Research Article

Efficacy of Neoadjuvant Chemotherapy plus Limb-Sparing Surgery for Osteosarcoma and Its Impact on Long-Term Quality of Life

Shixia Jing,1 Fengling Ding,2 Yinghong Yuan,3 Jing An,4 and Qiang He5

1Central Sterile Supply Department, Nanchong Central Hospital, Nanchong 637000, China
2Department of Orthopedics, Rizhao Central Hospital, Rizhao 276800, China
3Department of Surgery, Nanchong Central Hospital, Nanchong 637000, China
4Department of Infectious Diseases, Rizhao Central Hospital, Rizhao 276800, China
5The Affiliated Nanhua Hospital, Department of Hand Surgery, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China

Correspondence should be addressed to Qiang He; hewaib24213@163.com

Received 6 May 2022; Revised 26 May 2022; Accepted 28 June 2022; Published 8 August 2022

Academic Editor: Tian jiao Wang

Copyright © 2022 Shixia Jing et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To assess the efficacy of neoadjuvant chemotherapy plus limb-sparing surgery for osteosarcoma and its impact on long-term quality of life. Methods. Between August 2016 and December 2018, 90 patients with osteosarcoma treated in Nanchong Central Hospital were recruited and divided at a ratio of 1:1 to receive limb-sparing surgery (control group) or limb-sparing surgery plus neoadjuvant chemotherapy (study group) by random number table methods. The clinical endpoints were clinical efficacy and long-term quality of life. Results. Limb-sparing surgery plus neoadjuvant chemotherapy was associated with a significantly higher efficacy versus limb-sparing surgery alone. Limb-sparing surgery plus neoadjuvant chemotherapy resulted in a significantly higher Enneking score and a higher good function rating of patients versus limb-sparing surgery. The two groups showed a high but similar 1-year survival rate. Patients given limb-sparing surgery plus neoadjuvant chemotherapy showed significantly higher 2-year and 3-year survival and a longer mean survival versus those receiving limb-sparing surgery alone. Limb-sparing surgery plus neoadjuvant chemotherapy resulted in significantly higher scores of role emotional, mental health, physical function, and social function and a lower bodily pain score than limb-sparing surgery alone. Limb-sparing surgery plus neoadjuvant chemotherapy was associated with significantly lower fatigue, nausea and vomiting, dyspnea, constipation, and diarrhea scores and a significantly higher health status score versus monotherapy of limb-sparing surgery. Conclusion. Neoadjuvant chemotherapy plus limb-sparing surgery improves the postoperative limb function and long-term quality of life of patients with osteosarcoma, which shows great potential for clinical promotion.

1. Introduction

Osteosarcoma is a common malignant bone tumor with an annual incidence of about 4-5 per one million people as reported by epidemiological statistics [1, 2]. The main clinical symptoms are skeletal and joint pain with progressive exacerbation, accompanied by local masses and venous rage. The male-to-female incidence ratio of osteosarcoma is approximately 3:2, with approximately 60% of patients with osteosarcoma being under 25 years of age [3, 4]. The most involved body parts are the distal femur, proximal tibia, and the medullary end of the proximal humerus. Clinical reports indicate that osteosarcoma is associated with complications such as pain, tissue remission, limited joint motion, and muscle atrophy, which may severely compromise prognosis and threaten patients’ lives. The mortality of the disease remains at a high level despite early and timely treatment [5]. Pathological findings show that osteosarcoma is highly malignant, and the closer the tumor site is to the trunk, the poorer the long-term survival of patients [6].

Radical surgery is indicated for the treatment of osteosarcoma, and limb-sparing surgery is currently considered
2. Materials and Methods

2.1. Research Subjects. In this prospective, randomized, controlled, single-blinded trial, 90 patients with osteosarcoma treated in Nanchong Central Hospital between August 2016 and December 2018 were recruited and divided at a ratio of 1 : 1 to receive limb-sparing surgery (control group) or limb-sparing surgery plus neoadjuvant chemotherapy (study group) by random number table methods. Both patients and family members voluntarily signed the consent form. This study was ethically approved by the Ethical Committee of Nanchong Central Hospital (No. 2016/12-335).

2.2. Inclusion and Exclusion Criteria. Inclusion criteria: patients aged 18–70 years, with a diagnosis of osteosarcoma of limbs confirmed by imaging and pathological examination, with stage IIA-IIB (Enneking stage), and with an expected survival of more than one year were included.

Exclusion criteria: patients with heart, liver, kidney, and other vital organ insufficiencies, with relevant contraindications to treatment, and with metastases by the time of diagnosis were excluded.

2.3. Treatment Methods. Patients in the control group were treated with limb-sparing surgery and given conventional adjuvant chemotherapy postoperatively.

Limb-sparing surgery: complete extraperitoneal resection (incision margin at least 5 cm from the tumor) [9] was performed, and the necrosis rate of the resected tumor was assessed postoperatively. Patients with a necrosis rate ≥90% were treated with the same chemotherapy regimen and dose of postoperative adjuvant chemotherapy, and patients with a necrosis rate <90% were treated with salvage chemotherapy at an appropriate dose. The duration of postoperative conventional adjuvant chemotherapy was 4 cycles.

Patients in the study group were treated with neoadjuvant chemotherapy plus limb-sparing surgery as follows: after diagnosis, adequate hydration and diuresis were performed 1 day before chemotherapy. The patients received neoadjuvant chemotherapy using the epirubicin (EPI) + cisplatin (DDP) + methotrexate (MTX) + ifosfamide (IFO) regimen. They received 90 mg/m² of EPI on days 1–3, 100 mg/m² of DDP on day 1, and 10 mg/m² of MTX on days 4–10. Each drip was completed within 6 h, followed by 1 dose (15000 mg/m²) of calcium folinic acid through intravenous injection every 6 h for a total of 12 doses. On days 15–19, IFO 2000 mg/m² was administered intravenously, and the drip was completed within 6 h, followed by an additional intravenous dose of a-mercapto ethane sulfonic acid sodium salt 400 mg every 6 h for 3 times, as shown in Figure 1. A total of 2 cycles of chemotherapy were administered with 21 days as 1 cycle. After the completion of chemotherapy, limb-sparing surgery was performed, and the surgical procedures were the same as those in the control group. Postoperative chemotherapy was administered in 4 cycles, similar to preoperative chemotherapy.

2.4. Outcome Measures

(1) Clinical efficacy: the clinical efficacy was evaluated according to the neoadjuvant chemotherapy efficacy assessment criteria, which were classified as complete response (CR), partial response (PR), and progressive disease (PD). CR: patients’ symptoms were significantly reduced or disappeared. PR: patients’ symptoms were reduced. PD: patients’ clinical symptoms were unrelieved.

(2) Limb function: six months after treatment, the postoperative functional assessment criteria of Enneking limb musculoskeletal system tumor surgical reconstruction were used to evaluate the limb activity function of the two groups, respectively. The evaluation was performed with regard to six aspects, namely, muscle strength, psychological tolerance, joint mobility, pain, limb stability, and living ability, with 5 points for each item. The postoperative functional assessment grading standard was divided into four levels: excellent, good, moderate, and poor, with ≥24 points as excellent, 18–23 points as good, 12–17 points as moderate, and ≤12 points as poor.
(3) Survival: patients were followed up at home or by telephone for 3 years, and the survival of the two groups was recorded and compared separately.

(4) Quality of life: six months after treatment, the MOS 36-item short-form health survey (SF-36) health measurement scale was used to assess the patients’ quality of life, and the modified quality of life measurement scale for cancer patients (EortcQLQC.30) was used to assess the symptoms and health status of the two groups.

2.5. Statistical Analysis. SPSS 22.0 was used for data analyses, and GraphPad Prism 8 was used for image rendering. The measurement data were expressed as (X ± s) and processed using the t-test. The count data were expressed as the number of cases (rate) and analyzed using the chi-square test. Differences were considered statistically significant at P < 0.05.

3. Results

3.1. Baseline Data. In the control group, there were 27 males and 18 females, aged between 19 and 45 (29.88 ± 5.23) years old, with a Karnofsky Performance Scale (KPS) score of 71.62 ± 5.33 points and a maximum tumor diameter of 6.02 ± 1.74 cm. There were 19 cases of the femur, 16 cases of the tibia, and 10 cases of the humerus in terms of tumor sites. In the study group, there were 25 males and 20 females, aged between 20 and 43 (29.94 ± 5.82) years old, with a KPS score of 72.01 ± 4.96 points and a maximum tumor diameter of 5.74 ± 1.93 cm. There were 21 cases of the femur, 15 cases of the tibia, and 9 cases of the humerus in terms of tumor sites. The baseline data of the two groups were comparable (all P > 0.05) (Table 1).

3.2. Clinical Efficacy. In the control group, there were 14 (31.11%) cases of CR, 21 (46.67%) cases of PR, and 10 (22.22%) cases of PD, with the efficacy of 77.78%. In the study group, there were 21 (46.67%) cases of CR, 22 (48.89%) cases of PR, and 2 (4.44%) cases of PD. Limb-sparing surgery plus neoadjuvant chemotherapy was associated with a significantly higher efficacy versus limb-sparing surgery alone (P < 0.05) (Table 2).

3.3. Limb Function. Limb-sparing surgery plus neoadjuvant chemotherapy resulted in a significantly higher Enneking score (25.98 ± 3.17 vs. 24.23 ± 2.81) and a higher good function rating result (82.22%, including 21 cases of excellent, 16 cases of good, 5 cases of moderate, and 3 cases of poor) versus limb-sparing surgery (57.78%, including 15 cases of excellent, 11 cases of good, 9 cases of moderate, and 10 cases of poor) (P < 0.05) (Table 3).

3.4. Survival. The two groups showed a high but similar 1-year survival rate (P > 0.05). Patients given limb-sparing surgery plus neoadjuvant chemotherapy showed significantly higher 2-year and 3-year survival and a longer mean survival (91.11%, 84.44%, and 33.72 ± 1.08) versus those receiving limb-sparing surgery alone (80.00%, 60.00%, and 29.56 ± 0.88) (P < 0.05) (Table 4).

3.5. Quality of Life. Limb-sparing surgery plus neoadjuvant chemotherapy resulted in significantly higher scores of role emotional, mental health, physical function, and social function and a lower bodily pain score (86.88 ± 7.23, 81.08 ± 5.49, 75.31 ± 6.17, 86.94 ± 3.23, and 62.18 ± 6.77) versus limb-sparing surgery (80.17 ± 6.06, 77.23 ± 5.17, 51.57 ± 6.13, 49.29 ± 8.19, and 70.11 ± 5.84) (P < 0.05) (Figure 2). Limb-sparing surgery plus neoadjuvant chemotherapy was associated with significantly lower fatigue, nausea and vomiting, dyspnea, constipation, and diarrhea scores (42.27 ± 4.17, 25.26 ± 3.68, 27.54 ± 3.92, 35.57 ± 2.88, and 25.18 ± 5.07) versus limb-sparing surgery (54.84 ± 4.68, 39.85 ± 4.54, 39.01 ± 4.08, 57.68 ± 5.14, and 39.28 ± 4.17) (P < 0.05), and combined therapy also resulted in a significantly higher health status score (67.21 ± 2.34) versus monotherapy (56.88 ± 2.73) (P < 0.05) (Table 5).

4. Discussion

The results of the present study showed a significantly higher clinical efficacy achieved by limb-sparing surgery plus neoadjuvant chemotherapy (95.56%) versus limb-sparing surgery alone (77.78%). Small metastatic lesions can be mostly unobservable to naked eyes or even imaging, so
radical surgery may fail to achieve a satisfactory therapeutic effect. The application of neoadjuvant chemotherapy plays an important role in improving the therapeutic effect and prolonging the survival of patients [16]. The reason for a higher efficacy after combined therapy herein may be that cisplatin is a broad-spectrum anticancer chemotherapeutic agent, which, similar to ifosfamide, acts nonspecifically on the cell division cycle and effectively impedes DNA replication and the expansion and cross-linking of tumor cells to kill cancer cells. Methotrexate is an antifolate antitumor drug that prevents tumor cell synthesis mainly by blocking dihydrofolate reductase inhibition, thereby inhibiting tumor cell growth and regeneration [17].

Osteosarcoma is a relatively drug-resistant tumor, and the effect of single-drug therapy is modest. The combination of antitumor drugs is to kill tumor cells in each cycle, improve the therapeutic effect of patients, and reduce the occurrence of drug resistance [18]. Patients in the present study were required to continue treatment with a chemotherapy regimen after surgical treatment, and the chemotherapy regimen was adjusted according to patients’ clinical symptoms to reduce the risk of recurrence and metastasis, which was in line with the findings of Luo et al. [19]. Moreover, in the present study, limb-sparing surgery plus neoadjuvant chemotherapy resulted in significantly higher Enneking scores, good function rating results, 2-year and 3-year survival, mean survival, and quality of life versus limb-sparing surgery alone, suggesting that the use of neoadjuvant chemotherapy combined with limb-sparing surgery was effective in improving patients’ limb movement function, survival outcomes, and long-term quality of life. The reason may be that epirubicin directly infiltrates into DNA bases, causing DNA strands to protrude into tumor cells, disrupting the synthesis of DNA and RNA in tumor cells and the structure and function of tumor cell membranes; neoadjuvant chemotherapy reduces the difficulty of surgery and facilitates the successful preservation of limbs [20], thereby enhancing the long-term survival rate and quality of life of patients. However, there are still some shortcomings and deficiencies in this study. The small sample size may compromise the objectivity of the results and conclusions, and only one chemotherapy regimen was proposed in this study, which requires further investigation by future studies.

### Table 1: Comparison of baseline data (x ± s).

|                | Control group | Study group | t/χ² | P     |
|----------------|---------------|-------------|------|-------|
| Gender (male/female) | 27/18         | 25/20       | 0.182| 0.670 |
| Age (years)     | 29.88 ± 5.23  | 29.94 ± 5.82| 0.51 | 0.959 |
| KPS scores      | 71.62 ± 5.33  | 72.01 ± 4.96| 0.359| 0.720 |
| Maximum tumor diameter (cm) | 6.02 ± 1.74 | 5.74 ± 1.93 | 0.723| 0.472 |
| Tumor site      |               |             | 0.185| 0.912 |
| Femur           | 19            | 21          |      |       |
| Tibia           | 16            | 15          |      |       |
| Humerus         | 10            | 9           |      |       |

### Table 2: Comparison of clinical efficacy (%).

| Groups         | n   | CR (n, %) | PR (n, %) | PD (n, %) | Efficacy (n, %) |
|----------------|-----|-----------|-----------|-----------|-----------------|
| Control group  | 45  | 14 (31.11)| 21 (46.67)| 10 (22.22)| 35 (77.78)      |
| Study group    | 45  | 21 (46.67)| 22 (48.89)| 2 (4.44)  | 43 (95.56)      |
| χ²             | —   | 6.154     |           |           |                 |
| P              | —   | 0.013     |           |           |                 |

### Table 3: Comparison of limb function.

| Groups         | n   | Enneking scores (x ± s) | Good function rating (n, %) |
|----------------|-----|-------------------------|-----------------------------|
| Control group  | 45  | 24.23 ± 2.81            | 26 (57.78)                  |
| Study group    | 45  | 25.98 ± 3.17            | 37 (82.22)                  |
| t/χ²           | —   | 2.771                   |                             |
| P              | —   | 0.007                   |                             |

### Table 4: Comparison of survival.

| Groups         | n   | 1-year survival (n, %) | 2-year survival (n, %) | 3-year survival (n, %) | Mean survival (x ± s, month) |
|----------------|-----|------------------------|------------------------|------------------------|-----------------------------|
| Control group  | 45  | 41 (91.11)             | 36 (80.00)             | 27 (60.00)             | 29.56 ± 0.88                |
| Study group    | 45  | 44 (97.78)             | 41 (91.11)             | 38 (84.44)             | 33.72 ± 1.08                |
| t/χ²           | —   | 1.906                  | 3.552                  | 6.702                  |                             |
| P              | —   | 0.167                  | 0.049                  | 0.010                  | ≤0.001                      |
5. Conclusion

Neoadjuvant chemotherapy plus limb-sparing surgery improves the postoperative limb function and long-term quality of life of patients with osteosarcoma, which shows great potential for clinical promotion.

Data Availability

The data generated or analyzed during this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Shixia Jing and Fengling Ding contributed equally to this work.

References

[1] J. Ritter and S. S. Bielack, “Osteosarcoma,” Annals of Oncology, vol. 21, no. 7, 2010.
[2] M. Kansara, M. W. Teng, M. J. Smyth, and D. M. Thomas, “Translational biology of osteosarcoma,” Nature Reviews Cancer, vol. 14, no. 11, pp. 722–735, 2014.
[3] C. Chen, L. Xie, T. Ren, Y. Huang, J. Xu, and W. Guo, “Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs,” Cancer Letters, vol. 500, pp. 1–10, 2021.
[4] A. Biazzo and M. De Paolis, “Multidisciplinary approach to osteosarcoma,” Acta Orthopaedica Belgiка, vol. 82, no. 4, pp. 690–698, 2016.
[5] F. Sadoughi, P. Maleki Dana, Z. Asemi, and B. Yousefi, “DNA damage response and repair in osteosarcoma: defects, regulation and therapeutic implications,” DNA Repair, vol. 102, Article ID 103105, 2021.
[6] K. Yamada and S. Matsumori, “Osteosarcoma,” Nihon Rinsho, vol. 28, pp. 1180–1181, 1970.
[7] G. R. Schirò, S. Sessa, A. Piccioli, and G. Maccario, "Primary amputation vs. limb salvage in mangled extremity: a
systematic review of the current scoring system,” BMC Musculoskeletal Disorders, vol. 16, no. 1, 2015.

[8] M. Xu, Z. Wang, X. Yu, J. Lin, and Y. Hu, “Guideline for limb-salvage treatment of osteosarcoma,” Orthopaedic Surgery, vol. 12, no. 4, pp. 1021–1029, 2020.

[9] M. Fujiki, T. Kimura, and A. Takushima, “Limb-salvage surgery with vascular reconstruction after lower extremity sarcoma resection: a systematic review and meta-analysis,” Microsurgery, vol. 40, no. 3, pp. 404–413, 2020.

[10] F. De Vita, F. Giuliani, G. Galizia et al., “Neo-adjuvant and adjuvant chemotherapy of gastric cancer,” Annals of Oncology, vol. 18, 2007.

[11] C. Bumma, D. Perroni, G. L. Grecchi, G. Lauria, and M. Pautasso, “Neo-adjuvant chemotherapy,” Minerva Chirurgica, vol. 43, pp. 55–58, 1988.

[12] J. R. Brahim and D. S. Ettinger, “Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy,” Respirology, vol. 12, no. 3, pp. 320–325, 2007.

[13] A. Constantinidou, N. Sauve, S. Stacchiotti et al., “Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study,” ESMO Open, vol. 5, no. 4, Article ID e000787, 2020.

[14] E. Simpson and H. L. Brown, “Understanding osteosarcomas,” Journal of the American Academy of Physician Assistants, vol. 31, no. 8, pp. 15–19, 2018.

[15] G. Li, J. Li, C. Y. Hu, L. Tian, C. A. Lv, and L. J. Jin, “Limb-salvage treatment of malignant tumors of the limbs,” Journal of Biological Regulators & Homeostatic Agents, vol. 32, no. 4, pp. 891–897, 2018.

[16] K. K. Haynes and H. G. Rosenthal, “The ever-changing world of limb salvage surgery for malignant bone tumors,” Nursing Clinics of North America, vol. 55, no. 2, pp. 251–266, 2020.

[17] L. Yu, L. Deng, S. Zhu et al., “Limb-salvage outcomes of arterial repair beyond time limit at different lower-extremity injury sites,” Medical Science Monitor, vol. 27, Article ID e927652, 2021.

[18] S. R. Grobmyer, R. Maki, G. Demetri et al., “Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma,” Annals of Oncology, vol. 15, no. 11, pp. 1667–1672, 2004.

[19] B. Pearce, S. Laws, and R. Rainsbury, “Neo-adjuvant chemotherapy and surgical planning: survey of practice, attitudes, and opinions in the UK,” Breast Journal, vol. 26, no. 4, pp. 819–821, 2020.

[20] S. C. Morris, S. C. Nelson, and L. M. Zuckerman, “Limb salvage for musculoskeletal tumors in the austere environment: review of the literature with illustrative cases regarding considerations and pitfalls,” JAAOS: Global Research and Reviews, vol. 4, no. 10, Article ID e19.00172, 2020.